Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BREAKING: U.K. approves Pfizer and BioNTech’s COVID-19 vaccine

By Chris Newmarker | December 2, 2020

United Kingdom U.K. COVID-19The United Kingdom today approved its first COVID-19 vaccine, created through a partnership between Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX).

The Medicines and Healthcare products Regulatory Agency (MHRA) approval came after a “rolling review” in which assessment takes place as the packages of data become available from ongoing studies on a staggered basis. The idea is to evaluate a promising medicine or vaccine as quickly as possible during public health emergencies, with MHRA scientists and clinicians reviewing everything from clinical trials to manufacturing and quality controls to supply chain and distribution conditions.

“We are globally recognized for requiring high standards of safety, quality and effectiveness for any vaccine. Our expert scientists and clinicians worked tirelessly, around the clock, carefully, scientifically, robustly and rigorously poring over hundreds of pages and tables of data, methodically reviewing the data,” said MHRA chief executive Dr. June Raine.

“Vaccines are the most effective way to prevent infectious diseases. They save millions of lives worldwide,” Raine said in a news release.

The U.K. approval comes more than a week before FDA’s Vaccines and Related Biological Products Advisory Committee will consider whether to recommend U.S. approval of the Pfizer/BioNTech vaccine. An emergency use authorization is expected to quickly follow, with the government quickly shipping an initial 6.4 million doses of the vaccine to states and other local jurisdictions.

Pfizer currently specifies that its vaccine candidate should be stored at a super-cold –70° C., so the earlier U.K. approval should give U.S. officials a chance to evaluate how well the company’s dry ice storage containers work as the British distribute the vaccine.

The FDA advisory committee expects to evaluate a second COVID-19 vaccine application — from Moderna (NSDQ:MRNA)  — later in the month.

In the U.K., distribution will be prioritized by guidance from the country’s Joint Committee on Vaccination and Immunization (JCVI).

Pfizer and BioNTech announced an agreement with the U.K. in July that it would distribute 30 million doses of the vaccine in the country once it was authorized for emergency use, and was later increased to 40 million doses in October. Through the agreement, 40 million doses will occur throughout the rest of this year and into 2021 in stages to allocate vaccines to more vulnerable demographics.

Complete delivery fulfillment is expected in 2021.

Senior editor Danielle Kirsh contributed to this report. 

 

 


Filed Under: Uncategorized
Tagged With: BioNTech, coronavirus, covid-19, Medicines and Healthcare products Regulatory Agency (MHRA), Pfizer, United Kingdom
 

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Related Articles Read More >

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
From 1.5% to 5.9%: Deloitte digs into what’s fueling Big Pharma’s R&D IRR climb
Recce targets A$15.8M to advance anti-infectives into Phase 3 trials
Vial of Steroid injection with a syringe on black table and stainless steel background.
The true cost of steroid-toxicity 
3D illustration of Palm painful - skeleton x-ray, medical concept.
Q&A: AnaptysBio’s CMO on rosnilimab’s ‘compelling’ phase 2b RA results
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE